Irbesartan, an agiotensin II type 1 receptor blocker, has anabolic bone effects in diabetes, inhibiting the deleterious effects of oxidative stress mediated by AGEs/RAGE [42]. This evidence concerns the gene AGER and diabetes mellitus.